RT Journal Article
T1 Cerebrovascular Disease and Statins
A1 Beltrán Romero, Luis M.
A1 Vallejo-Vaz, Antonio J.
A1 Muñiz Grijalvo, Ovidio
K1 Atherosclerosis
K1 Cerebrovascular disease
K1 LDL-cholesterol
K1 Statins
K1 Stroke
K1 Aterosclerosis
K1 Trastornos cerebrovasculares
K1 LDL-colesterol
K1 Accidente cerebrovascular
AB Elevated low-density lipoprotein-cholesterol (LDL-C) is a causal factor for the development of atherosclerotic cardiovascular disease (ASCVD); accordingly, LDL-C lowering is associated with a decreased risk of progression of atherosclerotic plaques and development of complications. Currently, statins play a central role in any ASCVD management and prevention strategies, in relation to their lipid-lowering action and potentially to pleiotropic effects. After coronary artery disease, stroke is the most frequent cause of ASCVD mortality and the leading cause of acquired disability, a major public health problem. There is often a tendency to aggregate all types of stroke (atherothrombotic, cardioembolic, and haemorrhagic), which have, however, different causes and pathophysiology, what may lead to bias when interpreting the results of the studies. Survivors of a first atherothrombotic ischemic stroke are at high risk for coronary events, recurrent stroke, and vascular death. Although epidemiological studies show a weak relationship between cholesterol levels and cerebrovascular disease as a whole compared with other ASCVD types, statin intervention studies have demonstrated a decrease in the risk of stroke in patients with atherosclerosis of other territories and a decrease in all cardiovascular events in patients who have had a stroke. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial demonstrated the benefit of high doses of atorvastatin in the secondary prevention of ischemic stroke. In this review, we discuss the evidence, use and recommendations of statins in the primary and secondary prevention of stroke, and their role in other scenarios such as the acute phase of ischemic stroke, cerebral hemorrhage, cardioembolic stroke, small vessel disease, and cognitive impairment.
PB Frontiers
YR 2021
FD 2021-12-02
LK http://hdl.handle.net/10668/3744
UL http://hdl.handle.net/10668/3744
LA en
NO Beltrán Romero LM, Vallejo-Vaz AJ, Muñiz Grijalvo O. Cerebrovascular Disease and Statins. Front Cardiovasc Med. 2021 Dec 2;8:778740
DS RISalud
RD Apr 4, 2025